Exceptional Response to Fixed Duration Obinutuzumab and Venetoclax in a Patient with Chronic Lymphocytic Leukemia: A Case Report
The degree of pancytopenia and the exceptional clinical response to minimal dose of obinutuzumab by this patient suggests an unusual sensitivity to obinutuzumab.
Authors
- Maya Rosenberg
- Catherine Diefenbach (ORCID: https://orcid.org/0000-0003-1116-3246)
Institutions
- NYU Langone Health (US)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1159/000548901
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00